Compare PCRX & ADAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ADAM |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.9M | 826.7M |
| IPO Year | 2010 | 2003 |
| Metric | PCRX | ADAM |
|---|---|---|
| Price | $24.59 | $9.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $30.25 | $9.17 |
| AVG Volume (30 Days) | 636.8K | ★ 918.9K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 11.87% |
| EPS Growth | 107.44 | ★ 196.49 |
| EPS | 0.19 | ★ 0.87 |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | $5.08 |
| P/E Ratio | $129.84 | ★ $11.44 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $6.45 |
| 52 Week High | $27.66 | $10.36 |
| Indicator | PCRX | ADAM |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 58.63 |
| Support Level | $24.61 | $8.55 |
| Resistance Level | $25.06 | $10.36 |
| Average True Range (ATR) | 0.91 | 0.21 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 47.59 | 54.15 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.